Paul Matthias Diderichsen

Paul Matthias Diderichsen

Auto-generated profile, based on publicly available information

Paul Matthias Diderichsen

Certara USA, Inc. Radnor Pennsylvania USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
ASAbhishek G. Sathe
Abhishek G. Sathe
PDPaul M. Diderichsen
Paul M. Diderichsen
FFFloris Fauchet
Floris Fauchet
SPSee‐Chun Phan
See‐Chun Phan
SGSandhya Girish
Sandhya Girish
AOAhmed A. Othman
Ahmed A. Othman
Sacituzumab govitecan (SG), a Trop‐2‐directed antibody‐drug conjugate, is approved for patients with metastatic triple‐negative breast cancer (mTNBC) who received ≥2 prior systemic therapies (≥1 in metastatic setting). Exposure–response (E‐R) relationships between SG exposure and efficacy and safety outcomes were characterized in 277 patients with mTNBC using data from the phase I/II IMMU‐132‐01 and phase III ASCENT (IMMU‐132‐05) studies. Evaluated endpoints included complete response (CR), objective response rate (ORR), progression‐free survival (PFS), overall survival (OS), and safety endpoints (individual first worst grade of select adverse events (AEs)). E‐R analyses were also conducted for time to first dose reduction or delay. Patients received SG at 8 or 10 mg/kg intravenously on days 1 and 8 of a 21‐day cycle. Average SG‐related serum exposure over the treatment duration (until the event) was consistently the most significant exposure metric correlated with efficacy and safety endpoints. Higher average concentration over the treatment duration for SG (CAVGSG) was the best predictor of CR and ORR. The model‐predicted proportions of patients with CR and ORR at 10 mg/kg were 4.26% and 32.6%, respectively. Higher CAVG for total antibody was the best predictor of OS and PFS. The model‐predicted probability of OS at 12 months at median lactate dehydrogenase (227 IU/L) was 53%. The probability of grade ≥1 evaluated AEs and the risk of dose reductions and delays significantly increased with increasing CAVGSG. The model‐predicted proportions of patients with any‐grade AEs were 35.9%, 67.4%, 64.7%, and 67.1% for vomiting, diarrhea, nausea, and neutropenia, respectively (10 mg/kg dose group). Neutropenia was the only evaluated AE for which CAVGSG was significantly associated with grade ≥3 events. The clinically meaningful efficacy and manageable safety achieved with SG 10 mg/kg on days 1 and 8 of every 21‐day cycle dosing regimen supports the appropriateness of this clinical dosage in patients with mTNBC.

10 September 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
HWHan Witjes
Han Witjes
AKAmit Khatri
Amit Khatri
PDPaul M. Diderichsen
Paul M. Diderichsen
JMJaap Mandema
Jaap Mandema
AOAhmed A. Othman
Ahmed A. Othman
Risankizumab, an anti‐interleukin‐23 monoclonal antibody, achieved significantly (P < 0.001) greater Psoriasis Area and Severity Index (PASI) and static Physician Global Assessment (sPGA) clear or almost clear (0/1) responses than adalimumab in a phase III trial in patients with moderate‐to‐severe psoriasis. Meta‐analyses of the PASI 50, PASI 75, PASI 90, PASI 100, and sPGA0/1 responses after 16 weeks of treatment from eight (three for risankizumab and five for adalimumab) randomized, placebo‐controlled trials were conducted to estimate the efficacy difference between risankizumab and adalimumab. For PASI 75, PASI 90, PASI 100, and sPGA0/1 responses, the estimated effect differences (95% confidence interval) between risankizumab and adalimumab were 15.2% (10.1%, 20.4%), 23.7% (15.7%, 31.2%), 20.8% (13.0%, 28.7%), and 20.1% (13.7%, 26.1%), respectively. These results were consistent with the observed efficacy difference from the head‐to‐head phase III trial, which was not included in the meta‐analyses, providing independent, confirmatory evidence of the superior efficacy of risankizumab compared with adalimumab for treatment of moderate‐to‐severe psoriasis.

9 June 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MHMichael J. Hanley
Michael J. Hanley
PDPaul Diderichsen
Paul Diderichsen
BRBenjamin Rich
Benjamin Rich
ALAnna Largajolli
Anna Largajolli
ESEmilie Schindler
Emilie Schindler
NGNeeraj Gupta
Neeraj Gupta
Optimizing Ponatinib Treatment in CP‐CML (OPTIC) was a randomized, phase II dose‐optimization trial of ponatinib in chronic phase‐chronic myeloid leukemia (CP‐CML) resistant to ≥ 2 tyrosine kinase inhibitors or with T315I mutation. Patients were randomized to starting doses of 45‐, 30‐, or 15‐mg ponatinib once daily. Patients receiving 45‐ or 30‐mg reduced to 15‐mg upon achievement of ≤ 1% BCR::ABL1IS (≥ molecular response with 2‐log reduction (MR2)). The exposure‐molecular response relationship was described using a four‐state, discrete‐time Markov model. Time‐to‐event models were used to characterize the relationship between exposure and arterial occlusive events (AOEs), grade ≥ 3 neutropenia, and thrombocytopenia. Increasing systemic exposures were associated with increasing probability of transitioning from no response to ≥ MR1, and from MR1 to ≥ MR1, with odds ratios of 1.63 (95% confidence interval (CI), 1.06–2.73) and 2.05 (95% CI, 1.53–2.89) for a 15‐mg dose increase, respectively. Ponatinib exposure was a significant predictor of AOEs (hazard ratio (HR) 2.05, 95% CI, 1.43–2.93, for a 15‐mg dose increase). In the exposure‐safety models for neutropenia and thrombocytopenia, exposure was a significant predictor of grade ≥ 3 thrombocytopenia (HR 1.31, 95% CI, 1.05–1.64, for a 15‐mg dose increase). Model‐based simulations predicted a clinically meaningful higher rate of ≥ MR2 response at 12 months for the 45‐mg starting dose (40.4%) vs. 30‐mg (34%) and 15‐mg (25.2%). The exposure–response analyses supported a ponatinib starting dose of 45 mg with reduction to 15 mg at response for patients with CP‐CML.

11 April 2022 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
NGNeeraj Gupta
Neeraj Gupta
PPPhilippe B. Pierrillas
Philippe B. Pierrillas
MHMichael J. Hanley
Michael J. Hanley
SZSteven Zhang
Steven Zhang
PDPaul M. Diderichsen
Paul M. Diderichsen
Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non‐small cell lung cancer (mNSCLC) with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum‐based chemotherapy. This population pharmacokinetic (PK) analysis describes the PK of mobocertinib and its active metabolites, AP32960, and AP32914, using data from two phase I studies in healthy volunteers (n = 110) and two phase I/II studies in patients with mNSCLC (n = 317), including the pivotal phase I/II study. The plasma PK of mobocertinib, AP32960, and AP32914 were well‐characterized by a joint semimechanistic model that included two compartments for mobocertinib with absorption via three transit compartments, two compartments for AP32960, and one compartment for AP32914. The observed time‐dependency in PK was described by an enzyme compartment with drug and metabolite concentration‐dependent stimulation of enzyme production, resulting in the enzyme increasing the apparent clearance of mobocertinib, AP32960, and AP32914. Effects of healthy volunteer status (vs. patients with mNSCLC) on apparent oral clearance of all three moieties and on apparent central volume of distribution for mobocertinib were included as structural covariates in the final model. No clinically meaningful differences in mobocertinib PK were observed based on age (18–86 years), race, sex, body weight (37.3–132 kg), mild‐to‐moderate renal impairment (estimated glomerular filtration rate 30–89 ml/min/1.73 m2 by modification of diet in renal disease equation), or mild‐to‐moderate hepatic impairment, suggesting that no dose adjustment is required based on these covariates in patients with mNSCLC.

23 October 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
YVYulia Vugmeyster
Yulia Vugmeyster
ARAbhigyan Ravula
Abhigyan Ravula
ERElisabeth Rouits
Elisabeth Rouits
PDPaul Matthias Diderichsen
Paul Matthias Diderichsen
HKHuub Jan Kleijn
Huub Jan Kleijn
KVKarthik Venkatakrishnan
Karthik Venkatakrishnan
Xevinapant, an oral inhibitor of apoptosis protein (IAP) inhibitor, demonstrated efficacy in combination with chemoradiotherapy in a randomized phase II study (NCT02022098) in patients with locally advanced squamous cell carcinoma of the head and neck at 200 mg/day on days 1–14 of a 3‐week cycle. To confirm 200 mg/day as the recommended phase III dose (RP3D), we integrated preclinical, clinical, pharmacokinetic/pharmacodynamic (PK/PD), and exposure–response modeling results. Population PK/PD modeling of IAP inhibition in peripheral blood mononuclear cells in 21 patients suggested the pharmacologically active dose range was 100–200 mg/day, with a trend for more robust inhibition at the end of the dosing interval at 200 mg/day based on an indirect response model. Additionally, the unbound average plasma concentration at 200 mg/day was similar to that associated with efficacy in preclinical xenograft models. Logistic regression exposure–response analyses of data from 62 patients in the phase II study showed exposure‐related increases in probabilities of locoregional control at 18 months (primary end point), overall response, complete response, and the radiosensitization mechanism‐related composite safety end point “mucositis and/or dysphagia” (P < 0.05). Exposure–response relationships were not discernible for 12 of 13 evaluated safety end points, incidence of dose reductions, and time to first dose reduction. Quantitative integration of all available data, including model‐derived target inhibition profiles, positive exposure‐efficacy relationships, and lack of discernible exposure‐safety relationships for most safety end points, supports selection of xevinapant 200 mg/day on days 1–14 of a 3‐week cycle as the RP3D, allowing for successive dose reductions to 150 and 100 mg/day to manage adverse events.

23 May 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
JSJaydeep K. Srimani
Jaydeep K. Srimani
PDPaul M. Diderichsen
Paul M. Diderichsen
MHMichael J. Hanley
Michael J. Hanley
RLRichard Labotka
Richard Labotka
NGNeeraj Gupta
Neeraj Gupta
Ixazomib has been approved in several countries as single‐agent maintenance therapy in newly diagnosed multiple myeloma, in both posttransplant and transplant‐ineligible settings, based on two phase III studies. In these maintenance studies, patients were initially administered 3 mg ixazomib, escalating to 4 mg if the initial dose level was well tolerated through Cycles 1–4. Here, we report the results of exposure–response analyses of TOURMALINE‐MM4, wherein relationships between exposure and clinical response, dose adjustments, and selected adverse events were evaluated. Similar progression‐free survival benefits were observed across the range of ixazomib exposures achieved in the study. Moreover, increased ixazomib exposures corresponded to a higher probability of maintaining complete response. Exposure was not a significant predictor (P > 0.05) of hematological adverse events (anemia, neutropenia, thrombocytopenia) and peripheral neuropathy; however, higher exposures did correlate to increased probabilities of experiencing diarrhea, vomiting, nausea, rash, and fatigue. While ixazomib exposure was not predictive of dose reductions, lower apparent clearance values (corresponding to higher systemic exposures) were correlated with a reduced likelihood of escalating to the 4 mg dose. Thus, the dose titration approach balanced patient benefit and risk; it ensured that only patients for whom the 3 mg dose was safe/tolerable escalated to the higher dose, while maximizing the fraction of patients (85%) who were able to derive additional clinical benefit at 4 mg. Collectively, these results highlight the value of safety‐driven personalized dosing to maximize patient benefit/risk.